FENTREPID
A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis
Inclusion Criteria
- Multiple Sclerosis
- **other criteria will apply
For more information, call Allison Emborsky at 716-558-3543 or email aemborsky@dentinstitute.com. You can also visit:
https://fenstudies.com/fentrepid/
or
Subscribe To Our Newsletter
Sign up to receive email updates on announcements, new services added, company updates & more!
Want to participate in a study?
Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.